Preventive treatment status among adults presenting with status migrainosus: a retrospective emergency department cohort study

Background: Status migrainosus (SM) is a disabling migraine complication that remains poorly characterized in emergency settings, particularly regarding prevention at presentation. We aimed to characterize documented preventive-treatment status among adults presenting to the emergency department (ED) with SM and explore associated baseline clinical characteristics. Methods: We conducted a single-center retrospective cohort study of adults with International Classification of Headache Disorders, 3rd edition (ICHD-3)-defined SM between January 2017 and August 2025. The screening frame comprised 1426 migraine-coded ED discharges; all 19 SM-coded encounters and 187 predefined high-suspicion encounters underwent manual chart review. The first confirmed SM presentation was the index presentation. Between-group comparisons were exploratory, with Benjamini-Hochberg false discovery rate (FDR) correction across 24 comparisons as a sensitivity analysis. Results: Forty-two patients met ICHD-3 criteria and accounted for 65 SM-related ED presentations. At index presentation, 10/42 (23.8%; exact 95% confidence interval 12.1–39.5%) had documented ongoing preventive therapy and 32/42 (76.2%) did not. Patients presenting despite preventive therapy had nominally higher rates of chronic migraine (62.5% vs. 10.0%, p = 0.009), anxiety disorders (40.0% vs. 6.2%, p = 0.021), chronic pain comorbidity (30.0% vs. 3.1%, p = 0.036), selective serotonin reuptake inhibitor use (40.0% vs. 6.5%, p = 0.024), and cannabis use (33.3% vs. 3.4%, p = 0.035). None remained significant after FDR correction (minimum q = 0.174). Conclusions: Most identified patients with ICHD-3-confirmed SM in this cohort were not receiving documented migraine preventive therapy. Exploratory secondary analyses identified nominal differences in several baseline clinical characteristics according to preventive-treatment status, but none remained significant after FDR correction. These findings provide a rationale for prospective investigation of the clinical significance of preventive-treatment status in SM, including whether SM occurring without prevention identifies an opportunity for preventive reassessment and whether SM occurring during prevention reflects underlying disease burden, treatment-related factors, or true preventive-treatment failure.

Status migrainosus; Chronic migraine; Migraine prevention; Emergency department; Migraine chronification

[1] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.

[2] Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: an 11-year retrospective analysis. Cephalalgia. 2014; 34: 633–637.

[3] VanderPluym JH, Mangipudi K, Mbonde AA, Gritsch D, Caronna E, Halker Singh RB, et al. Incidence of status migrainosus in Olmsted County, Minnesota, United States: characterization and predictors of recurrence. Neurology. 2023; 100: e255–e263.

[4] Orr SL, Turner A, Kabbouche MA, Horn PS, O’Brien HL, Kacperski J, et al. The profile and prognosis of youth with status migrainosus: results from an observational study. Headache. 2020; 60: 878–888.

[5] Iljazi A, Chua A, Rich-Fiondella R, Veronesi M, Melo-Carrillo A, Ashina S, et al. Unrecognized challenges of treating status migrainosus: an observational study. Cephalalgia. 2020; 40: 818–827.

[6] Rozen TD. Emergency department and inpatient management of status migrainosus and intractable headache. Continuum. 2015; 21: 1004–1017.

[7] Wang X, Zhang L, Lai Y, Li Y, Liu X. Clinical characteristics and treatment of patients hospitalized with status migrainosus: a retrospective analysis. Acta Neurologica Belgica. 2025; 125: 1007–1014.

[8] Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024; 44: 3331024241269735.

[9] Mungoven TJ, Henderson LA, Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Frontiers in Pain Research. 2021; 2: 705276.

[10] Cosentino G, Antoniazzi E, Cavigioli C, Guaschino E, Ghiotto N, Castaldo M, et al. Offset analgesia as a marker of dysfunctional pain modulation in episodic and chronic migraine. The Journal of Headache and Pain. 2025; 26: 50.

[11] Sic A, Bogicevic M, Brezic N, Nemr C, Knezevic NN. Chronic stress and headaches: the role of the HPA axis and autonomic nervous system. Biomedicines. 2025; 13: 463.

[12] Generaal E, Vogelzangs N, Macfarlane GJ, Geenen R, Smit JH, Penninx BW, et al. Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders. BMC Musculoskeletal Disorders. 2014; 15: 227.

[13] Scher AI, Buse DC, Fanning KM, Kelly AM, Franznick DA, Adams AM, et al. Comorbid pain and migraine chronicity: the chronic migraine epidemiology and outcomes study. Neurology. 2017; 89: 461–468.

[14] Ling YH, Pan LH, Chen SP, Chen WT, Liu HY, Wang SJ, et al. Comorbidity with fibromyalgia predicted poorer outcomes in patients with chronic migraine on flunarizine: prospective proof-of-concept study. Cephalalgia. 2025; 45: 3331024251353412.

[15] Ray JC, Matharu M, Hutton E. Relationship of migraine and other forms of chronic pain. Handbook of Clinical Neurology. 2024; 199: 517–524.

[16] Polanco M, Gárate G, Sánchez-Gudín J, Madera J, Pascual J, González-Quintanilla V. Real-world lessons with fremanezumab as the third available CGRP monoclonal antibody in a third-level hospital: focus on the factors predicting response. Journal of Clinical Medicine. 2025; 14: 1054.

[17] Sarkar AK, Ghanbarian E, Fanning KM, Urani A, Cadiou F, Lipton RB, et al. Impact of anxiety and depression on migraine-related disability: results from the headache assessment via digital platform in the United States (HeAD-US) study. Clinical Neurology and Neurosurgery. 2025; 258: 109172.

[18] Nijs J, Malfliet A, Nishigami T. Nociplastic pain and central sensitization in patients with chronic pain conditions: a terminology update for clinicians. Brazilian Journal of Physical Therapy. 2023; 27: 100518.

[19] Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021; 61: 1021–1039.

[20] Mayers M, Wogayehu J, Ailani J. Status migrainosus—a narrative review. Current Neurology and Neuroscience Reports. 2025; 25: 53.

[21] Singh TD, Cutrer FM, Smith JH. Episodic status migrainosus: a novel migraine subtype. Cephalalgia. 2018; 38: 304–311.

[22] Pozo-Rosich P, Caronna E, Sacco S, Peres MFP, Ashina S, Özge A, et al. Early treatment in migraine—a call to shift prevention from attacks to disease progression: a position statement from the International Headache Society. Cephalalgia. 2025; 45: 3331024251387721.